Biology

Phase II/III GAIN trial results: atuzaginstat for disease modification in Alzheimer’s disease

Caspase-6-cleaved tau in Alzheimer’s disease

Changes in Rhes distribution associated with tau accumulation and neuronal vulnerability

Investigating differences in selective neuronal vulnerability in typical and atypical AD

Mass spectrometry-based proteomics identifies progressive changes in tau PTMs over time

Beyond amyloid & tau: neuroinflammation, rhes & proteomics

Advances in methodology for structural biology of neurodegeneration

Detecting microglial activation in Alzheimer’s disease

The potential of lecanemab for the treatment of early Alzheimer’s disease

The impact of sex on Alzheimer’s disease presentation in adults with Down syndrome

AD pathology isn’t always associated with memory loss

What underlies the manifestation differences seen in atypical AD?

Bringing plasma biomarkers into clinical practice: what does the future hold?

Beyond Aβ and p-Tau: novel biomarkers under investigation for Alzheimer’s disease

The potential of NfL as a biomarker in neurodegenerative diseases

Inflammatory biomarkers for the prediction of dementia onset